Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS
Status:
Terminated
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
This phase 2 study is designed to evaluate the safety and activity of TH-4000 (Tarloxotinib),
a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell
carcinoma of the head and neck or skin.